# 1. Financial Performance ## A. Key Figures * **EBITDA:** **₹98.6 Cr** FY26 (+15.8%) · **₹25.2 Cr** Q4 FY26 (+26%) * **EBITDA Margin:** **31.8%** FY26 (-200 bps) · **31%** Q4 FY26 (Stable) * **Pre-Ind AS Metrics (FY26):** **₹75 Cr** EBITDA · **₹39 Cr** PAT ## B. Revenue Growth * **Sustained Expansion Momentum:** Robust top-line growth driven by the execution of an integrated diagnostic infrastructure plan and network expansion. * **Long-term Compounding:** The company maintained a strong three-year CAGR, significantly scaling from its **FY23 baseline of ₹190 crore**. ## C. Margins & Profitability * **Unit Economics:** Mature centers demonstrate superior profitability with margins reaching **36% to 37%**, well above the current blended average. * **Margin Compression Drivers:** Annual EBITDA and PAT margins faced pressure from increased fixed costs, pre-operative expenses for new centers, and higher depreciation/finance costs. * **Segment Parity:** Profitability remains balanced between pathology and radiology; pathology’s higher consumable costs are offset by lower reporting fees, while radiology follows the inverse pattern. ## D. Cost Structure * **Variable Professional Fees:** Doctor payments (radiologists, pathologists, and consultants) are pegged at a consistent percentage of revenue, ensuring cost alignment with volume. * **OPD Fee Sharing:** The company operates a high-payout model for consultants, retaining **15%** of fees for on-premise consultations. * **Operating Leverage Headwinds:** Other expenses are elevated at nearly half of revenue, primarily due to a **INR 30 crore** annual rental bill linked to aggressive geographic scaling. --- # 2. Network & Capacity ## A. Key Figures * **Network Size:** **68** Total Centers as of March 2026 * **FY26 Expansion:** **2** Hubs · **11** Spokes · **3** PPP Centers * FY27 Guidance: 5 Hubs · 8 Spokes * **Planned Capex:** **₹70 Cr** for FY27 expansion ## B. Hub & Spoke Strategy * **Model Optimization:** Reinforced leadership in Eastern India by leveraging a differentiated hub-and-spoke architecture and a unified diagnostic/consultation platform. * **Asset-Light Scaling:** Expansion strategy focuses on establishing new hubs supported by asset-light spoke centers to maximize the utilization of central reference infrastructure. ## C. Geographic Expansion * **Regional Diversification:** Transitioning from a West Bengal-centric player to a diversified regional entity with new specialized hubs in **Bihar, Tripura, and Jharkhand**. * **Northeast Momentum:** Strongest non-core traction observed in **Guwahati**, supported by plans to add two additional centers in the region this year. * **Brand Leverage:** Strategic entry into Tripura aims to capitalize on high brand awareness among the local Bengali-speaking population. ## D. Infrastructure & Automation * **Capacity Multiplier:** Implementation of Roche pathology automation has successfully increased testing throughput by **3x**. * **Specialized Facilities:** Established a high-end MRI training center featuring top-tier radiological expertise to bolster diagnostic capabilities. --- # 3. Product & Service Performance ## A. Key Figures * **Revenue Mix:** **48.85%** Pathology · **44.26%** Radiology · **6.89%** Doctor Consultancy * Genomics Revenue: ₹1 Cr Q4 FY27 (+₹2.5 Mn QoQ) · ₹35 Lakhs Monthly Run Rate ## B. Diagnostic Mix & Strategy * **Balanced Portfolio:** Revenue split closely aligns with industry standards; management intends to maintain this equilibrium to capture the full patient prescription value. * **Internal Referral Engine:** The Doctor Consultancy and Polyclinic segment serves as a strategic funnel, driving high-margin diagnostic volumes into the core pipeline. * **Growth Drivers:** Top-line momentum is increasingly supported by high-value infection-related testing, moving away from historical pandemic-related testing spikes. ## C. Specialized Verticals & Genomics * **High-Complexity Focus:** Growth is pivoting toward specialized platforms like **Fetomat** (fetal medicine) and targeted genomics, which command premium margins and establish reference lab status. * **Genomics Expansion:** Rapid scaling of molecular capabilities into advanced segments including **oncology-focused panels**, **whole genome testing**, and **AI-integrated screening**. * **Incremental Momentum:** The nascent genomics vertical is demonstrating steady sequential growth, contributing significant new revenue streams as of the latest quarter. ## D. Clinical Offerings * **Niche Clinical Expansion:** Launch of specialized **dementia, epilepsy, and oncology-focused clinics** (cervical and ovarian cancer) signals a strategic push into early detection services across Eastern India. --- # 4. Customer & Operational Metrics ## A. Key Figures * **Revenue Metrics:** **₹2,264** Revenue per Patient · **₹720** EBITDA per Patient * **Center Performance:** **₹4.57 Cr** Avg. Revenue per Center (FY26) · **36%–37%** Mature Center EBITDA Margin * **Q4 Center Split:** **₹16.3 Mn** Mature Center Revenue (37% EBITDA) · **₹5 Mn** New Center Revenue (-5.5% EBITDA) ## B. Patient Volume & Revenue Mix * **Volume Deceleration:** Patient growth slowed to low single digits despite a **20% to 25%** expansion in the center network (increasing from **55** to **68** locations). * **Premiumization Strategy:** Significant spike in realization per patient driven by a portfolio shift toward specialized genomic testing and high-value radiology. * **Customer Loyalty:** Maintained a consistent repeat customer rate of approximately **40%**, supporting base-load volumes. ## C. Center Maturity & Profitability * **Unit Economics Gap:** A stark contrast remains between mature centers and new facilities (<2 years old), though management notes the performance gap is narrowing as new sites scale. * **Breakeven Timelines:** Small centers reach unit-level breakeven in **5–6 months**, while large centers require **9–12 months**; corporate-level breakeven typically follows **1–2 quarters** later. * **Post-Listing Expansion:** The **20** centers added since the IPO are ramping up revenue, with several reaching unit breakeven, though EBITDA-level contribution is expected in **6 months**. ## D. Operational Efficiency * **Technology Integration:** Deployment of **1.5T helium-free MRI** technology at Calcutta Medical College is expected to enhance patient throughput and operational efficiency in high-complexity clinical areas. --- # 5. Technology & Innovation ## A. Key Figures * **Oncology Testing TAT:** **48–72 hours** via Genexus NGS platform (vs. 14–21 days previously) ## B. AI & Digital Infrastructure * **Operational Digitization:** Transitioned all laboratory operations to a **unified online platform**, integrating AI-enabled workflows and digital reporting to streamline infrastructure. * **Strategic R&D:** Partnered with **IIT Kharagpur** via MoU to develop AI-driven early Alzheimer’s detection using routine MRIs; clinical trials are currently in progress. ## C. Platform Integration & Data Integrity * **In-Sourcing Advantage:** Acquisition of the **Genexus NGS platform** (first in Eastern India) eliminates outsourcing needs and drastically reduces turnaround times for genomic testing. * **Patient Data Consolidation:** Utilization of a diligent IT system to maintain single patient profiles ensures historical record access, though this high data integrity may result in lower optical patient volume growth versus peers. --- # 6. Risks & Diagnostic Factors ## A. Key Figures * **Patient Growth:** **1.7%** Q4 Seasonality Impact · **2% to 3%** Recent Quarter * **Cannibalization Impact:** **5% to 10%** Performance dip in existing centers ## B. Seasonality & Growth Dynamics * **Seasonal Headwinds:** Modest patient volume growth in the most recent periods is primarily attributed to the conclusion of the winter season. * **Strategic Cannibalization:** High center density in core Kolkata clusters causes a temporary performance dip in established sites; however, regional net growth remains positive as new centers ramp up rapidly. * **Patient Acquisition Profile:** New centers in core geographies are seeing significant overlap with existing databases, indicating a shift in patient convenience rather than entirely new market capture. ## C. Operational & Regulatory Factors * **Licensing Recovery:** Recent delays in center openings were tied to election-related setbacks in power and licensing; **two** centers have since opened, with the final **two** expected this month. * **Data Integrity & Metrics:** Management cautions against using patient growth as a primary KPI due to the lack of unique national IDs and data entry inconsistencies that may inflate peer figures. * **Infrastructure Monitoring:** Performance is evaluated via prescription and patient-level data rather than specific utilization metrics for MRI and CT hardware. --- # 7. Guidance & Outlook ## A. Key Figures * **Revenue Growth Guidance:** **~15%** FY27 and beyond * **EBITDA Margin Targets:** **~33%** FY27 (Normalized) · **~35%** Medium-term · **38%–39%** Long-term * **Network Expansion:** **68** centers FY26 · **82** centers FY27 (+14) · **100** centers FY28 ## B. Revenue & Margin Dynamics * **Growth Composition:** Future top-line expansion is heavily weighted toward new center contributions, with mature facilities providing high single-digit organic growth. * **Margin Evolution:** Near-term profitability is tempered by pre-operative expenses from aggressive expansion; however, rapid center maturity (typically **6–8 months**) supports a trajectory toward high-30s margins. * **Profitability Drivers:** Long-term margin expansion is predicated on operating leverage, centralized procurement efficiencies, and a shift toward high-complexity testing such as genomics. ## C. Strategic Roadmap * **Regional Focus:** Strategic priority remains replicating the high-margin model through systematic penetration across Eastern and Northeastern India. * **Operational Excellence:** Management is prioritizing increased throughput and capacity utilization at nascent centers alongside technology-driven patient experience enhancements. * **Conservative Positioning:** Despite historical outperformance, management maintains a disciplined and conservative forward guidance to ensure sustainable scaling.